Latest news with #treatmentOptions
Yahoo
30-06-2025
- Business
- Yahoo
Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations
"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the Growing Cancer Therapeutics Market" BOSTON, June 30, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions" is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029 at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029. This report provides a comprehensive analysis of the global market for cancer therapeutics. It covers the history, forms, pathophysiology, stages, and mechanisms of cancer metastasis and recurrence. The report also examines the disease burden through cancer epidemiology. It discusses various treatment patterns, including non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, chemotherapy, combinatorial therapy) approaches. Additionally, it analyzes the most frequently used products, clinical trials, new product approvals, and the growth prospects of the regions of North America, Europe, Asia-Pacific, and the Rest of the World. Profiles of leading companies and their strategies in the cancer treatment sector are also included. This report is particularly relevant today due to the urgent need for new treatments for metastatic cancers, which are responsible for about 90% of cancer-related deaths. The aggressive nature of metastatic disease and the challenge of overcoming resistance to existing therapies highlight the importance of this market. The rapid evolution of combination therapies which integrate immunotherapy, targeted therapy, and chemotherapy, offers promising advances in increasing treatment efficacy and overcoming resistance, making this a critical area of focus. The factors driving the market's growth include: Approval of Oncology Drugs: Faster approval processes, like the FDA's accelerated pathway, help new cancer drugs reach patients sooner, encouraging innovation. Technological Advances: Innovations such as personalized medicine, AI in treatment planning, and immunotherapy make cancer treatments more effective. Increasing Cancer Incidence: The rise in the number of cancer cases due to aging populations and lifestyle changes drive the demand for new treatments. Promising Late-Stage Drugs: Many new drugs in late-stage trials show potential for better efficacy and fewer side effects, offering hope for improved cancer care. Request a sample copy of the report on the global market for cancer therapeutics emphasizing recurrent and metastatic divisions. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $108.1 billion Market size forecast $168.0 billion Growth rate CAGR of 7.7% from 2024 to 2029 Segments covered By Cancer Type and Region Regions covered North America, Europe, Asia-Pacific, and the Rest of the World (RoW) Countries covered The U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Japan, China, India and South Korea Market drivers • Approval of oncology drugs. • Technological advances in cancer treatments. • Increasing incidence of cancer. • Promising drugs in the late stage of the pipeline. Interesting facts: Common metastatic cancers include breast, lung, prostate, colorectal cancer, and melanoma. According to the National Cancer Institute, about 30% of women with early-stage breast cancer may eventually develop Stage 4 (metastatic) breast cancer. In 2024, Takeda's fruquintinib (FRUZAQLA) was approved by the European Commission for treating metastatic colorectal cancer in adults. In 2024, the US FDA approved Bristol Myers Squibb's Opdivo, combined with Cisplatin and Gemcitabine, for treating unresectable or metastatic urothelial carcinoma in adults. Emerging startups: Oricell Therapeutics: Clinical-stage biotech company that develops effective and affordable cell therapies for the global patient community. Oricell's pipeline includes drugs for liquid as well as solid tumors. Cybrexa: Platform technology company that makes it possible for small-molecule anti-cancer medications to target tumors and metastases without antigens and to penetrate deep tissue. The company's goal is to help cancer patients live more satisfying lives by providing them with new treatment options. Asher Biotherapeutics Inc.: Cis-targeted immunotherapies are a novel approach pioneered by Asher. Its immunotherapies activate only the specific immune cell types that support the intended therapeutic response. The indiscriminate action of conventional immunotherapies on various cell types, which leads to suboptimal efficacy and adverse effects, will be addressed by this novel approach. The report addresses the following questions: What is the projected market size and growth rate?• The global market for cancer therapeutics emphasizing recurrent and metastatic divisions was valued at $108.1 billion in 2023 and is projected to reach $168.0 billion by the end of 2029. What factors are driving the growth of the market?• The increasing incidence of cancer, approvals of oncology drugs, and technological advances in cancer treatments are driving the market's growth. Which market segments are covered in the report?• This report segments the market scope into cancer types. The report covers lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, cervix cancer, bladder cancer, kidney cancer, pancreas cancer, ovary cancer, and other cancers. Which cancer type segment will be dominant through 2029?• Lung cancer will dominate the cancer therapeutics market with an emphasis on recurrent and metastatic divisions. Which region has the largest market share?• The North American market was valued at $48.1 billion in 2023 and is projected to reach $75.3 billion in by the end of 2029, at a CAGR of 7.8% during the forecast period. Market leaders include: ABBVIE INC. AMGEN INC. ASTRAZENECA BAYER AG BRISTOL-MYERS SQUIBB CO. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. JOHNSON & JOHNSON SERVICES INC. LILLY MERCK & CO. INC. NOVARTIS AG PFIZER INC. REGENERON PHARMACEUTICALS INC. SANOFI TAKEDA PHARMACEUTICAL CO. LTD. Related reports: Artificial Intelligence (AI) in Cancer: The report on AI technology in cancer applications outlines the market's current and future potential, analyzing drivers, restraints, and opportunities. It projects market trends through 2029, segmented by application (screening, diagnosis, therapy, drug discovery), cancer type (breast, lung, prostate, etc.), and end user (hospitals, diagnostic centers). The report also analyzes the market in the regions of North America, Europe, Asia-Pacific, and the Rest of the World, with profiles of major companies and their recent developments. Global Oncology Pharmaceuticals Market: The report provides a comprehensive analysis of the global oncology pharmaceuticals market, covering drug types like targeted therapy, immunotherapy, chemotherapy, and hormone therapy. It examines market revenues by cancer type, including lung, breast and prostate. The report also analyzes regional market revenues for North America, Europe, Asia-Pacific, and the Rest of the World. Additionally, it includes profiles of leading companies, a discussion of the competitive landscape, pipeline and patent analysis, and a discussion of market drivers and restraints. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC
Medscape
23-06-2025
- Health
- Medscape
ACG Updates Guidance on Crohn's Disease Management
The American College of Gastroenterology (ACG) has issued updated guidance on the management of Crohn's disease (CD) that reflects the surge in development of therapeutic options available since 2018, when the last guideline was published. These newer treatment options include interleukin-23 (IL-23) blockers risankizumab, mirikizumab, and guselkumab; the anti-IL-12/23 agent ustekinumab; the JAK inhibitor upadacitinib; and the anti-integrin vedolizumab. The intent of the guideline is to suggest 'preferable approaches' to CD management established through 'interpretation and collation of scientifically valid research, derived from extensive review of published literature,' said the writing group, led by Gary Lichtenstein, MD, director, Inflammatory Bowel Disease Center, Hospital of the University of Pennsylvania, Philadelphia. When exercising clinical judgment, the authors advise healthcare providers to 'incorporate this guideline along with patient's needs, desires, and their values to care for patients fully and appropriately with CD.' The guideline is intended to be 'flexible, not necessarily indicating the only acceptable approach,' and shared decision-making with the patient is advised, they stressed. The 40-page guideline was published online earlier this month in American Journal of Gastroenterology, along with a one-page visual highlights summary . From Diagnosis to Surgery The incidence of CD has steadily increased over the past several decades, and both the diagnosis and treatment of patients with CD has evolved since 2018. Table 1 of the guideline outlines all 35 recommendations for management of CD, which span diagnosis, endoscopy, medical management (broken down by mild-to-moderately severe disease with a lower or higher risk for disease progression), fistulizing CD, when to refer to surgery, and postoperative care (according to low and high risk for postoperative recurrence). Table 2 of the guideline offers 59 'key concepts' covering clinical features, natural history, intestinal malignancy, diagnosis, disease modifiers, and medical and surgery management. In making a diagnosis, it's important to consider clinical presentation as well as endoscopic, radiologic, histologic, and pathologic findings, the authors said. They advise using fecal calprotectin (cutoff > 50-100 ug/g) to differentiate inflammatory from noninflammatory disease of the colon. Routine endoscopic surveillance for colorectal cancer in patients with Crohn's colitis is also recommended. Medical Treatment 'Medical treatment of CD is usually categorized into induction and maintenance therapy,' the authors wrote. Treatment regimens are usually chosen with 'a goal to achieve clinical and biomarker response within 12 weeks of treatment initiation followed by durable steroid-free control of disease activity including both clinical and endoscopic remission.' However, objective outcomes like endoscopic improvements have only recently been added to clinical trials, they noted. The authors stressed that early initiation of advanced therapy is 'key' for optimal outcomes and that failure of conventional therapy before initiation of advanced therapy is not required. For mild to moderately severe disease (with a lower risk for progression), oral mesalamine is not recommended for induction or maintenance; ileal release budesonide is recommended for induction but not maintenance; and sulfasalazine should be considered only for those with symptomatic mild colonic CD. For moderate to severe CD (with a higher risk for progression) there are 17 recommendations, including: Oral corticosteroids are recommended for short-term induction of remission but not maintenance. Azathioprine and 6-mercaptopurine are not recommended for induction of remission but are recommended for maintenance of remission, with thiopurine methyltransferase testing done before initiation. However, given the adverse effect profile of thiopurine monotherapy, newer safer agents for maintenance should be considered. Methotrexate for maintenance of steroid-free remission is suggested. Anti-TNF agents (IV infliximab; SC adalimumab or certolizumab pegol) are recommended for induction and maintenance; SC infliximab for maintenance only; TB and hepatitis B status should be checked before treatment. Vedolizumab, ustekinumab, upadacitinib, guselkumab, mirikizumab, and risankizumab are all options for induction and maintenance. For fistulizing CD, infliximab, adalimumab, antibiotics, upadacitinib, vedolizumab or ustekinumab are recommended options for induction of remission. Referral to Surgery In terms of when to refer to surgery, patients with an intra-abdominal abscess > 2 cm should be treated with drainage and antibiotics. Patients with symptomatic fibrostenotic strictures or abdominal abscesses should be considered for surgery, the authors advised. In patients with surgically induced remission, colonoscopy 6-12 months after surgery is recommended to assess for early recurrent CD. Patients with a low post-op risk of recurrence can be observed. Patients with a high risk of post-op recurrence should consider starting advanced therapy shortly after resection with an anti-TNF agent or vedolizumab. High-risk patients include active smokers, those with penetrating disease and prior CD resections. The guidance also emphasizes the importance of addressing disease modifiers including NSAID use, cigarette smoking, diet, and management of stress, depression, and anxiety.
Medscape
21-05-2025
- Health
- Medscape
Ulcerative Colitis: Colectomy Risk Dips in the 21st Century
The risk for colectomy declined over the past two decades among Finnish patients with newly diagnosed ulcerative colitis (UC), particularly between 2013 and 2020, when several advanced treatment options were available. METHODOLOGY Researchers in Finland utilized data from a population-based registry between January 2000 and December 2020 to determine the risk for colectomy in patients with newly diagnosed UC and compare risks across different eras. They identified 32,108 patients, of whom 2195 underwent colectomy (median age at surgery, 39.4 years; 60.5% men); patients were stratified into three groups — 2000-2005 (prebiological era), 2006-2012, and 2013-2020 — according to the time of diagnosis and the availability of treatments. Participants were also stratified by age at diagnosis into paediatric (< 20 years), adult (20-59 years), and older adult (≥ 60 years) groups. TAKEAWAY: The cumulative risk for colectomy was 1.0% at 1 year, 4.7% at 5 years, and 7.3% at 10 years following UC diagnosis. Compared with the prebiological era, the 2013-2020 era saw a reduction in the 1-year and 5-year risks for colectomy (incidence rate ratio [IRR], 0.757 and 0.70, respectively), and the 2006-2012 era saw a reduction in the 10-year risk (IRR, 0.87). The paediatric population experienced a lower risk for surgery in the 2013-2020 era than in previous eras, whereas the risk for surgery among older adult patients remained unchanged from earlier periods. Compared with the adult population, the paediatric population faced a higher risk for surgery (IRR, 1.69), whereas the older adult population had a lower risk (IRR, 0.79). IN PRACTICE: "The risk of colectomy among Finnish UC patients has decreased in the 21st century. The risk reduction coincides with the use of advanced medical therapy and more ambitious treatment targets, and it can also be seen in children and adolescents. The elderly have lower colectomy rates than do younger newly diagnosed patients, but their risk has remained constant," the authors wrote. SOURCE: This study was led by Kristi Kontola, Department of Internal Medicine, Wellbeing Services County of South Ostrobothnia, Seinäjoki, Finland. It was published online on May 13, 2025, in the Journal of Crohn's and Colitis . LIMITATIONS: This study was limited by the lack of follow-up data and the use of non-inflammatory bowel disease registries. The Social Insurance Institution registry was not updated with clinical data after initial reimbursement approval; hence, it may have included misdiagnosed cases. Additionally, the national registries used in this study did not contain detailed clinical information, preventing the analysis of important parameters such as disease extent and specific indications for colectomy. DISCLOSURES: This study was supported by the Wellbeing Services County of South Ostrobothnia and the Mary and Georg C. Ehrnrooth Foundation. One author reported being a national representative of ECCO, a board member of the Finnish Society of Gastroenterology, and a member of the scientific advisory board of the Finnish Coeliac Society. Another author reported being a board member of the IBD subdivision of the Finnish Society of Gastroenterology and a consultant for the Nursing Research Foundation. Some also reported receiving personal fees from various pharmaceutical companies.
CNN
19-05-2025
- Climate
- CNN
Doctor explains possible treatment options for Biden's cancer
Doctor explains possible treatment options for Biden's cancer Former President Joe Biden was diagnosed with an 'aggressive form' of prostate cancer, according to a statement from his personal office, and it has spread to his bones. Dr. Jamin Brahmbhatt, a urologist from Orlando Health, explains the possible treatment options for the former president. 01:25 - Source: CNN Vertical Top News 17 videos Doctor explains possible treatment options for Biden's cancer Former President Joe Biden was diagnosed with an 'aggressive form' of prostate cancer, according to a statement from his personal office, and it has spread to his bones. Dr. Jamin Brahmbhatt, a urologist from Orlando Health, explains the possible treatment options for the former president. 01:25 - Source: CNN California fertility clinic damaged in explosion At least one person is dead and four others injured in a Palm Springs, California, explosion outside a fertility clinic, according to the FBI's assistant director in charge of Los Angeles' field office. CNN's Jessica Dean reports. 00:47 - Source: CNN Rare dust storm blankets Chicago The Chicago skyline disappeared momentarily as a wall of dust blew through the city. The National Weather Service attributed this to 60 to 70 mph winds that blew over dry farmlands, collecting dust and blowing it through the Chicago area, according to CNN affiliate WBBM. 00:32 - Source: CNN CNN correspondent walks through aftermath of deadly tornado A storm that produced a devastating tornado in the St. Louis, Missouri, area Friday afternoon has left multiple people dead, according to local authorities. CNN's Julia Vargas Jones walks through some of the aftermath where one resident said an entire floor to a nearby building was blown away. 00:44 - Source: CNN Zelensky says Putin was 'afraid' for talks Neither Ukrainian President Volodymyr Zelensky or Russian President Vladimir Putin are attending peace talks in Istanbul after days of confusion. In a meeting in Albania, Zelensky said Putin was 'afraid' to come to Turkey for talks and that Russian delegation in Istanbul is of a 'very low level.' 00:38 - Source: CNN Lawmakers fall asleep during hearing Republican Rep. Blake Moore and Democratic Rep. Debbie Dingell both appeared to fall asleep during what were at-times contentious debates over provisions in President Donald Trump's sweeping tax and spending cuts package. 01:01 - Source: CNN Springsteen criticizes Trump administration during show Bruce Springsteen has criticized President Trump's administration on stage during a performance at the start of his UK tour in Manchester. 01:15 - Source: CNN Zelensky warns 'no time for playing games' Ukrainian President Volodymyr Zelensky said he will head to Turkey and wait for Russian President Vladimir Putin for potential ceasefire talks; but he set some minimal goals for the meeting. CNN's Nick Paton Walsh reports. 01:26 - Source: CNN Mistaken arrest leads to teen's ICE detention A northwest Georgia community voted overwhelmingly for President Donald Trump. Now it's desperately trying to save its residents from being deported. CNN's Dianne Gallagher reports. See the full story on CNN tonight. 01:28 - Source: CNN Deepfake detectors fooled by expert With AI technology creating more and more realistic deepfakes, detectors are not up to the challenge of realizing what is real and what is fake, according to an industry expert. CNN's Isabel Rosales looks at how this technology can be bypassed and what you can do to protect yourself. An earlier version of this video gave the incorrect title for Perry Carpenter. He is the Chief Human Risk Management Strategist at KnowBe4. 02:41 - Source: CNN Arizona wildfire burns more than 2,000 acres A wildfire in Apache County, Arizona has burned more than 2,000 acres and destroyed multiple structures, with several areas under evacuation orders, according to the Arizona Department of Forestry and Fire Management. 00:30 - Source: CNN 200 people rescued from flooded Maryland school Roughly 200 people have been rescued from an elementary school in Maryland after heavy rains brought severe flooding to the region. Waters started to reach the second floor of Westernport Elementary School, according to the county's emergency services department. 00:39 - Source: CNN Syrians react after Trump says he plans to lift sanctions President Donald Trump announced he plans to lift sanctions on Syria during a speech in Saudi Arabia citing the fall of the Assad regime as grounds for the release of pressure on the country. Syrians spared little time before celebrating. 00:51 - Source: CNN Coates describes moment Cassie cried on the stand Cassie Ventura, the former girlfriend of Sean 'Diddy' Combs and one of his accusers, testified in his federal criminal trial. CNN's Laura Coates breaks down key moments from her testimony. 00:52 - Source: CNN New book reveals 'shocking' claim that Biden didn't recognize Clooney President Joe Biden did not recognize George Clooney when he arrived for a record-breaking June 2024 fundraiser the movie star was co-hosting, according to a forthcoming book from CNN's Jake Tapper and Axios' Alex Thompson. 01:06 - Source: CNN See Edan Alexander's reunion with family after release Edan Alexander, the last known living American hostage in Gaza, was released by Hamas and reunited with his family on Monday, ending an 18-month ordeal that began with the militant group's October 7 attack. 00:40 - Source: CNN
CNN
19-05-2025
- Climate
- CNN
Doctor explains possible treatment options for Biden's cancer
Doctor explains possible treatment options for Biden's cancer Former President Joe Biden was diagnosed with an 'aggressive form' of prostate cancer, according to a statement from his personal office, and it has spread to his bones. Dr. Jamin Brahmbhatt, a urologist from Orlando Health, explains the possible treatment options for the former president. 01:25 - Source: CNN Vertical Top News 17 videos Doctor explains possible treatment options for Biden's cancer Former President Joe Biden was diagnosed with an 'aggressive form' of prostate cancer, according to a statement from his personal office, and it has spread to his bones. Dr. Jamin Brahmbhatt, a urologist from Orlando Health, explains the possible treatment options for the former president. 01:25 - Source: CNN California fertility clinic damaged in explosion At least one person is dead and four others injured in a Palm Springs, California, explosion outside a fertility clinic, according to the FBI's assistant director in charge of Los Angeles' field office. CNN's Jessica Dean reports. 00:47 - Source: CNN Rare dust storm blankets Chicago The Chicago skyline disappeared momentarily as a wall of dust blew through the city. The National Weather Service attributed this to 60 to 70 mph winds that blew over dry farmlands, collecting dust and blowing it through the Chicago area, according to CNN affiliate WBBM. 00:32 - Source: CNN CNN correspondent walks through aftermath of deadly tornado A storm that produced a devastating tornado in the St. Louis, Missouri, area Friday afternoon has left multiple people dead, according to local authorities. CNN's Julia Vargas Jones walks through some of the aftermath where one resident said an entire floor to a nearby building was blown away. 00:44 - Source: CNN Zelensky says Putin was 'afraid' for talks Neither Ukrainian President Volodymyr Zelensky or Russian President Vladimir Putin are attending peace talks in Istanbul after days of confusion. In a meeting in Albania, Zelensky said Putin was 'afraid' to come to Turkey for talks and that Russian delegation in Istanbul is of a 'very low level.' 00:38 - Source: CNN Lawmakers fall asleep during hearing Republican Rep. Blake Moore and Democratic Rep. Debbie Dingell both appeared to fall asleep during what were at-times contentious debates over provisions in President Donald Trump's sweeping tax and spending cuts package. 01:01 - Source: CNN Springsteen criticizes Trump administration during show Bruce Springsteen has criticized President Trump's administration on stage during a performance at the start of his UK tour in Manchester. 01:15 - Source: CNN Zelensky warns 'no time for playing games' Ukrainian President Volodymyr Zelensky said he will head to Turkey and wait for Russian President Vladimir Putin for potential ceasefire talks; but he set some minimal goals for the meeting. CNN's Nick Paton Walsh reports. 01:26 - Source: CNN Mistaken arrest leads to teen's ICE detention A northwest Georgia community voted overwhelmingly for President Donald Trump. Now it's desperately trying to save its residents from being deported. CNN's Dianne Gallagher reports. See the full story on CNN tonight. 01:28 - Source: CNN Deepfake detectors fooled by expert With AI technology creating more and more realistic deepfakes, detectors are not up to the challenge of realizing what is real and what is fake, according to an industry expert. CNN's Isabel Rosales looks at how this technology can be bypassed and what you can do to protect yourself. An earlier version of this video gave the incorrect title for Perry Carpenter. He is the Chief Human Risk Management Strategist at KnowBe4. 02:41 - Source: CNN Arizona wildfire burns more than 2,000 acres A wildfire in Apache County, Arizona has burned more than 2,000 acres and destroyed multiple structures, with several areas under evacuation orders, according to the Arizona Department of Forestry and Fire Management. 00:30 - Source: CNN 200 people rescued from flooded Maryland school Roughly 200 people have been rescued from an elementary school in Maryland after heavy rains brought severe flooding to the region. Waters started to reach the second floor of Westernport Elementary School, according to the county's emergency services department. 00:39 - Source: CNN Syrians react after Trump says he plans to lift sanctions President Donald Trump announced he plans to lift sanctions on Syria during a speech in Saudi Arabia citing the fall of the Assad regime as grounds for the release of pressure on the country. Syrians spared little time before celebrating. 00:51 - Source: CNN Coates describes moment Cassie cried on the stand Cassie Ventura, the former girlfriend of Sean 'Diddy' Combs and one of his accusers, testified in his federal criminal trial. CNN's Laura Coates breaks down key moments from her testimony. 00:52 - Source: CNN New book reveals 'shocking' claim that Biden didn't recognize Clooney President Joe Biden did not recognize George Clooney when he arrived for a record-breaking June 2024 fundraiser the movie star was co-hosting, according to a forthcoming book from CNN's Jake Tapper and Axios' Alex Thompson. 01:06 - Source: CNN See Edan Alexander's reunion with family after release Edan Alexander, the last known living American hostage in Gaza, was released by Hamas and reunited with his family on Monday, ending an 18-month ordeal that began with the militant group's October 7 attack. 00:40 - Source: CNN
